沙库巴曲缬沙坦联合曲美他嗪治疗慢性心力衰竭的效果及对NT-proBNP、CT-1、sICAM-1水平的影响  

Effect of sacubitril valsartan combined with trimetazidine in the treatment of chronic heart failure and its influences on the levels of NT-proBNP,CT-1 and sICAM-1

作　　者：秦亚妮 肖懿慧 QIN Yani;XIAO Yihui(Traditional Chinese Medicine Hospital of Huazhou District,Weinan 714100;the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China)

机构地区：[1]华州区中医医院,陕西渭南714100 [2]西安交通大学第一附属医院,陕西西安710061

出　　处：《临床医学研究与实践》2022年第22期67-70,共4页Clinical Research and Practice

摘　　要：目的探讨沙库巴曲缬沙坦联合曲美他嗪治疗慢性心力衰竭(CHF)的效果。方法选择2018年1月至2021年2月我院收治的126例CHF患者作为研究对象,根据随机数字表法将其分为对照组和观察组,各63例。对照组给予常规治疗加曲美他嗪,观察组在对照组基础上加沙库巴曲缬沙坦,比较两组的治疗效果。结果观察组的治疗总有效率高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的N端脑利钠肽前体(NT-proBNP)、心肌营养素-1(CT-1)、可溶性细胞间黏附分子-1(sICAM-1)水平均低于治疗前,且观察组低于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的心输出量(CO)、每搏输出量(SV)、左心射血分数(LVEF)、舒张早期血流速度峰值/舒张晚期血流速度峰值(E/A)高于治疗前,且观察组高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的环境、生理、社会关系、心理评分高于治疗前,且观察组高于对照组,差异具有统计学意义(P<0.05)。结论沙库巴曲缬沙坦联合曲美他嗪治疗CHF的效果显著,有利于调节机体NT-proBNP、CT-1、sICAM-1水平,改善患者心功能指标,提高生活质量,值得临床推广与应用。Objective To explore the effect of sacubitril valsartan combined with trimetazidine in the treatment of chronic heart failure(CHF).Methods A total of 126 patients with CHF admitted in our hospital from January 2018 to February 2021 were selected as the study objects.According to the random number table method,the patients were divided into control group and observation group,with 63 cases in each group.The control group was treated with conventional therapy plus trimetazidine,the observation group was additionally with sakubbatro valsartan on the basis of the control group,and the therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of N-terminal pro-brain natriuretic peptide(NT-proBNP),cardiotrophin-1(CT-1)and soluble intracellular adhesion molecule-1(sICAM-1)in the two groups were lower than those before treatment,those in the observation group were lower than the control group,and the differences were statistically significant(P<0.05).After treatment,the cardiac output(CO),stroke volume(SV),left ventricular ejection fraction(LVEF),early diastolic peak velocity/late diastolic peak velocity(E/A)in the two groups were higher than those before treatment,those in the observation group were higher than the control group,and the differences were statistically significant(P<0.05).After treatment,the scores of environment,physiology,social relations and psychology in the two groups were higher than those before treatment,those in the observation group were higher than the control group,and the differences were statistically significant(P<0.05).Conclusion The sakubatro valsartan combined with trimetazidine in the treatment of CHF has a significant effect,it is beneficial to regulate the levels of NT-proBNP,CT-1 and sICAM-1,improve the heart function indexes and the quality of life of patients,which is worthy of clinical promoti

关 键 词：沙库巴曲缬沙坦 曲美他嗪 慢性心力衰竭 心功能 

分 类 号：R541.6[医药卫生—心血管疾病]